Please assess the completion status of the following clinical trial:

Trial Title: Drug Study of Albuterol to Treat Acute Lung Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet the following three criteria within a 24-hour period:~  1. Acute onset of PaO2/FiO2 less than or equal to 300 (adjustments made for altitude where appropriate)~ 2. Bilateral infiltrates consistent with pulmonary edema on frontal chest radiograph~ 3. Requirement for positive pressure ventilation via endotracheal tube~* No clinical evidence of left-sided cardiac failure to account for bilateral pulmonary infiltrates~Exclusion Criteria:~* Greater than 48 hours since all inclusion criteria are met~* Neuromuscular disease that impairs ability to ventilate without assistance, (e.g., cervical spinal cord injury at level C5 or higher spinal cord injury amyotrophic lateral sclerosis, Guillain-Barré syndrome or myasthenia gravis)~* Pregnant or breast-feeding~* Severe chronic respiratory disease (i.e., chronic hypercapnia \[PaCO2 greater than 45 mmHg\], chronic hypoxemia \[PaO2 less than 55 mmHg on FiO2 = 0.21\], hospitalization within the last 6 months for respiratory failure \[PaCO2 greater than 50 mm Hg and/or PaO2 less than 55 mmHg on 0.21 FiO2\], secondary polycythemia, severe pulmonary hypertension \[mean PAP (pulmonary artery pressure) greater than 40 mmHg\], or ventilator dependency)~* Burns over greater than 40% of total body surface area~* Cancer or other irreversible disease or condition for which 6-month mortality is estimated to be greater than 50%~* Allogeneic bone marrow transplant within the 5 years prior to study entry~* Participant, surrogate, or physician is not committed to full support (Exception: a participant will not be excluded if he/she would receive all supportive care except for attempts at resuscitation from cardiac arrest)~* Severe chronic liver disease (Child-Pugh score of 11-15)~* Diffuse alveolar hemorrhage from vasculitis~* Morbid obesity (greater than 1kg/cm body weight.)~* Unwillingness or inability to utilize the ARDS network 6 ml / kg Predicted Body Weight (PBW) ventilation protocol~* Moribund participant and is not expected to survive 24 hours~* No intent to obtain central venous access for monitoring intravascular pressures~* Contraindication to aerosolized albuterol (see Appendix A.8 of the protocol for more information)~* Daily use (prior to study hospitalization) of inhaled beta agonist, corticosteroid, or oral leukotriene modifier~* Unwillingness of primary physician to discontinue inpatient beta agonist use~* Acute myocardial infarction or acute coronary syndrome within 30 days of study entry~* Severe congestive heart failure (see Appendix A5 of the protocol for more information)~* Participation in other experimental medication trial within 30 days of study entry with the exception of the ARDSNet pharmaconutrient nutrition trial (OMEGA)~* Heart rate greater than 85% of maximal predicted heart rate (MHR85) as calculated by MHR85 = 85% x (220-age)~* Currently receiving high frequency ventilation

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albuterol Sulfate (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).